Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Rivastigmine Actavis   
Auth. number : EU/1/11/693
INN : Rivastigmine
ATC: Anatomical main group: N - Nervous system
Therapeutic subgroup: N06 - Psychoanaleptics
Pharmacological subgroup: N06D - Anti-dementia drugs
Chemical subgroup: N06DA - Anticholinesterases
Chemical substance: N06DA03 - Rivastigmine
(See WHO ATC Index)
Indication: Symptomatic treatment of mild to moderately severe Alzheimer´s dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson´s disease.
Marketing Authorisation Holder: Actavis Group PTC ehf.
Reykjavíkurvegur 76-78, 220 Hafnarfjörður, Iceland

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/06/2011 Centralised - Authorisation EMEA/H/C/2036 (2011)4395 of 16/06/2011
01/12/2011 Centralised - Variation EMEA/H/C/2036/IB/1
Updated with Decision(2012)3618 of 25/05/2012
20/04/2012 Centralised - Variation EMEA/H/C/2036/IB/6/G
Updated with Decision(2012)3618 of 25/05/2012
01/06/2012 Centralised - Variation (2012)3618 of 25/05/2012
13/07/2012 Centralised - Variation EMEA/H/C/2036/IB/7
Updated with Decision(2012)7985 of 31/10/2012
06/11/2012 Centralised - Variation (2012)7985 of 31/10/2012
19/04/2013 Centralised - Variation EMEA/H/C/2036/X/5 (2013)2309 of 17/04/2013
27/08/2013 Centralised - Variation EMEA/H/C/2036/N/9
15/01/2014 Centralised - Variation EMEA/H/C/2036/N/10
12/08/2014 Centralised - Variation EMEA/H/C/2036/N/11